Antimalarial 4(1H)-pyridones bind to the Q(i) site of cytochrome bc(1)

作者：Capper Michael J; O'Neill Paul M; Fisher Nicholas; Strange Richard W; Moss Darren; Ward Stephen A; Berry Neil G; Lawrenson Alexandre S; Hasnain S Samar^*; Biagini Giancarlo A; Antonyuk Svetlana V

来源：Proceedings of the National Academy of Sciences of the United States of America, 2015, 112(3): 755-760.

DOI：10.1073/pnas.1416611112

• malaria
• cytochrome bc(1)
• drug discovery
• Plasmodium falciparum
• membrane protein

Cytochrome bc(1) is a proven drug target in the prevention and treatment of malaria. The rise in drug-resistant strains of Plasmodium falciparum, the organism responsible for malaria, has generated a global effort in designing new classes of drugs. Much of the design/redesign work on overcoming this resistance has been focused on compounds that are presumed to bind the Q(o) site (one of two potential binding sites within cytochrome bc(1)) using the known crystal structure of this large membrane-bound macromolecular complex via in silico modeling. Cocrystallization of the cytochrome bc(1) complex with the 4(1H)-pyridone class of inhibitors, GSK932121 and GW844520, that have been shown to be potent antimalarial agents in vivo, revealed that these inhibitors do not bind at the Q(o) site but bind at the Q(i) site. The discovery that these compounds bind at the Q(i) site may provide a molecular explanation for the cardiotoxicity and eventual failure of GSK932121 in phase-1 clinical trial and highlight the need for direct experimental observation of a compound bound to a target site before chemical optimization and development for clinical trials. The binding of the 4(1H)-pyridone class of inhibitors to Q(i) also explains the ability of this class to overcome parasite Q(o)-based atovaquone resistance and provides critical structural information for future design of new selective compounds with improved safety profiles.

• 出版日期2015-1-20